Abstract
Abstract
Electronic platforms provide an opportunity to improve the informed consent (IC) process by permitting elements shown to increase research participant understanding and satisfaction, such as graphics, self-pacing, meaningful engagement, and access to additional information on demand. However, including these elements can pose operational and regulatory challenges for study teams and institutional review boards (IRBs) responsible for the ethical conduct and oversight of research. We examined the experience of two study teams at Alzheimer’s Disease Research Centers who chose to move from a paper-based IC process to an electronic informed consent (eIC) process to highlight some of these complexities and explore how IRBs and study teams can navigate them. Here, we identify the key regulations that should be considered when developing and using an eIC process as well as some of the operational considerations eIC presents related to IRB review and how they can be addressed.
Publisher
Cambridge University Press (CUP)
Reference34 articles.
1. 32. Office of the Commissioner. Guide to informed consent. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent.
2. 8. Human Subjects Research Protections. Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators. https://www.federalregister.gov/documents/2011/07/26/2011-18792/human-subjects-research-protections-enhancing-protections-for-research-subjects-and-reducing-burden
3. A Memory and Organizational Aid Improves Alzheimer Disease Research Consent Capacity: Results of a Randomized, Controlled Trial
4. Informed consent: how much and what do patients understand?
5. The elderly and informed consent: Effects of vocabulary level and corrected feedback
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献